Tricyclic Antidepressant Toxicity

Back

Practice Essentials

Tricyclic antidepressants (TCAs) are so called because the original agents in this class contain a 3-ring molecular structure. However, some newer agents have a four-ring structure, so the term cyclic antidepressants (CAs) is more accurate. TCAs were first used in the 1950s to treat clinical depression. The first report of the adverse effects of TCA overdose came within 2 years of their entry into clinical use.[1]

Despite the increasing popularity of the selective serotonin reuptake inhibitors (SSRIs) in the treatment of depression, CAs continue to play an important role in the treatment of enuresis, obsessive-compulsive disorder, attention deficit hyperactivity disorder, school phobia, and separation anxiety in the pediatric population. In adults, indications for CAs include depression, neuralgic pain, chronic pain, and migraine prophylaxis. Some of the more commonly prescribed CAs include amitriptyline, desipramine, imipramine, nortriptyline, doxepin, clomipramine, and protriptyline. Maprotiline and mirtazapine, which are tetracyclic compounds, and amoxapine, a dibenzoxapine, are newer compounds that have a slightly different structure and toxicologic profile.

There is also a potential for TCA abuse and misuse outside of clinical indications and dosages. Subjects who admitted to the misuse of TCAs in a published case series have described effects of TCAs ranging from "a more sociable state" to a "'high' with euphoria, confusion, hallucinations, and a distorted sense of time".[2]

Onset of symptoms of CA toxicity typically occurs within 2 hours. Signs and symptoms include antimuscarinic, cardiovascular, and central nervous system effects. See Presentation and Workup. Treatment focuses on airway management, dysrhythmias, seizures, and hypotension. Sodium bicarbonate, benzodiazepines, and norepinephrine are the drugs of choice for these complications. See Treatment and Medication.

See also Tricyclic Antidepressant Toxicity in Pediatrics.

Pathophysiology

The CAs are well absorbed orally and undergo significant first-pass metabolism in the liver. They have a large volume of distribution and have long half-lives that generally exceed 24 hours. After the CAs are metabolized in the liver via glucuronic acid conjugation, they are then excreted through the kidneys.

The toxic effects of tricyclics are results of the following 4 main pharmacologic properties:

  1. Inhibition of norepinephrine and serotonin reuptake at nerve terminals
  2. Anticholinergic action
  3. Direct alpha-adrenergic blockade
  4. Membrane-stabilizing effect on the myocardium by blocking the cardiac myocyte fast sodium channels

TCAs also penetrate into the central nervous system (CNS). Given the appropriate dosage, a particular CA exerts its therapeutic antidepressant effects by increasing biogenic amines such as norepinephrine and serotonin at nerve terminals. The same mechanism is thought to be responsible for seizure occurrence in CA overdose. Altered mental status is also frequently seen in CA overdose and is mainly attributed to anticholinergic and antihistaminergic properties of CAs.

The effects of CA overdose on the cardiovascular system result mainly from the impediment of the cardiac conduction system. CAs, like the class IA antiarrhythmics, decrease the sodium influx through the fast sodium channels and consequently decrease the slope of phase 0, leading to the widened QRS complex that is typically seen on electrocardiograms of individuals with CA poisoning. An in vitro study reported that CAs also directly decrease myocardial contractility in a dose-dependent manner.[3]  

Epidemiology

Frequency

United States

In the 2022  American Association of Poison Control Centers' National Poison Data System Annual report, TCAs accounted for 3269 single exposures and 15 deaths. The CA most frequently ingested was amitriptyline, with 1916 exposures and 10 deaths, followed by doxepin (495 exposures and one death) and nortriptyline (340 exposures, 2 deaths). In addition, the tetracyclic antidepressant mirtazapine accounted for 1521 single exposures and no deaths.[4]

Mortality/Morbidity

Fatality before reaching a healthcare facility occurs in approximately 70% of patients attempting suicide with CAs. CA were the number one cause of fatality from drug ingestion until the last decade, when they were surpassed by analgesics. Only 2-3% of CA overdose cases that reach a healthcare facility result in death.

Sex- and age-related demographics

CA toxicity occurs in both men and women. However, the incidence of CA exposure is greater in women than in men because women are at a higher risk for suicide attempts.

CA toxicity occurs at all ages. Incidence of CA toxicity is most prevalent in persons aged 20-29 years. This again reflects the demographics of suicidal attempts.

History

History of suicidal ideation, prior suicide attempts, circumstances around ingestion, intended cyclic antidepressant (CA) usage, co-ingestants, time of ingestion, and dose ingested should be obtained from the patient directly and also from the patient's family.

CA exposure in children is common. The potentially lethal dose (with desipramine, imipramine, or amitriptyline) is as low as 15 mg/kg. Toddlers can exceed this threshold with only 1-2 pills and should be evaluated in the emergency department.[5]

Onset of symptoms typically occurs within 2 hours of ingestion, which corresponds to the peak CA serum level, which may range from 2-12 hours.

Determining which specific CA is involved may be helpful. Although amoxapine is associated with a higher incidence of seizures, maprotiline causes more severe cardiac toxicity.

Cardiovascular manifestations may include the following:

Central nervous system manifestations may include the following:

Peripheral autonomic system manifestations may include the following:

Physical Examination

Physical findings are usually consistent with the anticholinergic toxidrome and quinidine-like cardiotoxicity, and may include the following:

Laboratory Studies

Studies have shown that serum cyclic antidepressant (CA) level does not correlate well with severity of CA toxicity and is a poor predictor of clinical outcome. However, because multisubstance ingestion is common, routine screening for other potentially treatable toxicants is recommended (eg, acetaminophen, aspirin). Requests for the other serum toxicologic levels should be based on the clinical picture. For example, in patients with acidosis, assess for aspirin, ethylene glycol, and methanol.

Assess the following:

Point-of-care qualitative urine immunoassays for CA are available but are of limited clinical utility. Test results are positive for most tricyclic antidepressants in the subtherapeutic-to-toxic range, with the exception of clomipramine; therefore a positive result does not imply CA toxicity. False-positive results also occur due to cross-reactivity with other polycyclic medications. A urine immunoassay may be helpful when the patient's medications are unknown and CA toxicity is suspected on the basis of history, clinical presentation, and ECG findings.[6]

Imaging Studies

Chest radiography should be performed in cases of suspected aspiration or when respiratory symptoms are noted and may be used to rule out other causes of fever, tachycardia, and altered mental status.

Electrocardiography

Electrocardiography (ECG) is a highly sensitive tool, and a normal result can be used to rule out clinically significant CA toxicity. ECG is not specific enough to be used alone to diagnose CA overdose, but characteristic ECG changes can be a valuable adjunct to typical clinical features (eg, anticholinergic toxidrome, seizures, hypotension, tachycardia) in diagnosing CA toxicity.

ECG findings that can be observed in CA toxicity include the following[7] :

QRS complex duration can be used as a rough guide to the prognosis in TCA poisoning (eg, risk of seizures, dysrhythmias). A prospective study of 49 cases of acute TCA overdose found that patients with a QRS interval less than 100 milliseconds are unlikely to develop seizures and arrhythmias.[8] A reviw by Simon et al of 94,939 single-agent overdose cases that included CAs found that a normal QRS had a negative predictive value of 93% for seizures, 98.8% for ventricular dysrhythmias, and  97.2% for metabolic acidosis.[9]

Patients with a QRS interval of 100 milliseconds or longer have up to a 34% chance of developing seizures and up to a 14% chance of developing a life-threatening cardiac arrhythmia. With a QRS complex greater than 160 milliseconds, the chance of ventricular arrhythmias increases to 50%.[8]  A QRS interval greater than 100 milliseconds is the basis for treatment with bicarbonate (alkalinization).

The amplitude of the R wave in lead aVR and the ratio of the R/S waves in aVR are greater in patients who develop seizures or dysrhythmias. According to Liebelt et al, when the R wave in aVR equals 3 mm or more, the sensitivity and specificity for subsequent development of seizures or arrhythmias are 81% and 73%, respectively.[10]

A Brugada pattern was seen on ECG in 17% of patients with TCA toxicity in a retrospective study by Monteban-Kooistra et al.[11] The ECG abnormalities resolved after administration of sodium bicarbonate. A study of 98 consecutive cases of CA intoxication in France found that the mortality rate was 6.7% among patients with the Brugada pattern and 2.4% among patients without it. However, the difference was not statistically significant (P=0.39).[12]

Prehospital Care

Endotracheal intubation is necessary in a patient who is obtunded and unable to protect the airway. Intravenous access should be established as soon as possible. Administer intravenous fluid if the patient is hypotensive. Prompt transport of the patient to the nearest emergency department is implicit.

Evidence-based management guidelines for tricyclic antidepressant (TCA) poisoning are available from the American Association of Poison Control Centers (AAPCC). This guideline is outlined for poison control center personnel to assist in prehospital triage and management of patients with possible TCA ingestion/overdose. A brief summary of the prehospital evidence-based consensus management guideline is as follows[13] :

Refer to the AAPCC guideline for complete details.[13]

Emergency Department Care

The greatest risk of seizures and arrhythmias occurs within the first 6-8 hours of cyclic antidepressant (CA) ingestion. The treatment of an asymptomatic patient with a history of CA ingestion is mainly supportive therapy. For all patients with possible CA toxicity, airway protection, ventilation and oxygenation, intravenous fluids, cardiac monitoring, and performing electrocardiography (ECG) are all essential measures. The patient should be admitted to the ICU if hemodynamic instability and ECG changes are observed.

Consider early gastric decontamination using charcoal if the patient presents within 2 hours of ingestion.

Once suicidal ideation is ruled out and the patient remains asymptomatic for 6-8 hours postingestion without any ECG changes, the patient may be discharged home. If suicidal ideation is present, evaluation for admission to a psychiatric facility is mandatory.

Treatment considerations include the following:

GI decontamination may be helpful within the first several hours postingestion because CAs can slow gastric emptying through their anticholinergic activity.

Gastric lavage may be helpful in recovering and identifying the CA ingested. However, one study that compared the use of gastric lavage and activated charcoal versus charcoal alone showed no benefit in clinical outcome.[15] Usually, lavage is recommended for patients who developed significant toxicity requiring endotracheal intubation and who presented relatively soon after ingestion (within several hours).

Activated charcoal reduces the absorption of CAs. It may also be beneficial in cases of multisubstance ingestion. It should be administered only in patients who are able to protect the airway.

Endotracheal intubation is indicated if the patient cannot adequately maintain a safe airway.

Serum alkalinization with intravenous sodium bicarbonate has been the mainstay of therapy in CA-induced cardiovascular toxicity. QRS prolongation is most often the indication for serum alkalinization in CA toxicity. Not all physicians agree on what duration of QRS should be the indication for starting intravenous sodium bicarbonate therapy. However, about 88% of the poison control directors in the United States use a QRS of 100 milliseconds or greater as the threshold for use of intravenous sodium bicarbonate.[16]

Evidence suggests the reversal of toxic effects of CA (eg, QRS prolongation, myocardial depression) following serum alkalization and sodium loading with sodium bicarbonate. Sodium bicarbonate may be initially administered as an intravenous bolus at a dose of 1 - 2 mEq/kg. Serial ECG performed before and after administration of bicarbonate may be used to determine if cardiac conduction abnormalities are responsive to the therapy. Boluses of sodium bicarbonate may be repeated to treat cardiac conduction abnormalities and impaired contractility, with a maximum target blood pH of 7.50 - 7.55.

Alternatively, a bicarbonate infusion may be initiated after the bolus by adding 3 ampules of sodium bicarbonate (50 mEq each for a total of 150 mEq) to 1 L of 5% dextrose in water (D5W) and infusing at 1.5 - 2 times the maintenance rate. The same maximum target blood pH of 7.50 - 7.55 should be used for bicarbonate infusions. In patients who can not tolerate the volume of fluid associated with an infusion (eg, those with congestive heart failure, renal impairment, or end-stage renal disease), use of repeated boluses may be preferable.

Ventricular bradyarrhythmias, due to depressed atrioventricular conduction and automaticity, can be treated by placement of a temporary pacemaker. Alternatively, consider the use of a chronotropic agent.

Lidocaine, when used to treat ventricular arrhythmia, should be administered with caution to avoid precipitating seizures.

Intravenous lipid emulsion (ILE) has demonstrated efficacy in the treatment of local anesthetic agent–induced cardiotoxicity, in laboratory studies.[17] The theorized mechanism of action of ILE is the creation of "lipid sink" in the intravascular compartment, sequestering lipophilic drugs and reducing bioavailability.[18] No clinical studies have been done on ILE in the treatment of CA toxicity; however, case reports from Europe and New Zealand describe successful resuscitation using ILE therapy in patients demonstrating severe CA cardiotoxicity.[19, 20]

In the case studies published, ILE was used with success in patients with severe hemodynamic instability and QRS widening. ILE may be administered in a 1.5 mL/kg or 100 mL bolus (in adults) over 1 minute. This bolus may be repeated for patients in cardiac arrest or with recurrent toxicity. Alternatively, the bolus may be followed with an ILE infusion at 0.25 mL/kg/min for 30 - 60 minutes.[21]  

The seizures in CA toxicity are usually self-limited. The treatment of choice for prolonged or recurrent seizures in CA toxicity is a benzodiazepine. Most CA-induced seizures are usually brief and resolve prior to the administration of anticonvulsants. General anesthesia should be reserved for patients with status epilepticus who are unresponsive to the standard treatment regimen (eg, benzodiazepines, barbiturates, propofol). This may prevent hyperthermia and rhabdomyolysis.

A case study reported successful use of ILE therapy to treat refactory status seizures following ingestion of 3.0g of amozapine. In this case, seizures persisted after diazepam was administered.  Levetiracetam and phenobarbital were also administered with no effect. ILE was injected for over 1 minute with the patient's status seizures ceasing after 2 minutes. Within an hour after ILE, the seizures recurred and ILE was again administered. The seizures stopped and did not recur.[22]

The use of hypertonic saline in CA toxicity remains controversial. Although 7.5% hypertonic saline has been shown to correct hypotension and QRS widening in severe CA overdose in a swine model,[14] limited evidence supports the use of hypertonic saline in CA toxicity in humans. No study has adequately compared the efficacy of hypertonic saline versus sodium bicarbonate, and sodium loading may be the most important factor in the reversal of the symptoms of cyclic antidepressant toxicity.

Because of the large volume of distribution and high protein-binding characteristics of CAs, hemodialysis has not been shown to be effective in the treatment of CA overdose.

Despite continuous venovenous hemodiafiltration (CVVHDF) not usually being recommended in the management of TCA toxicity as it is ineffective at eliminating the toxin, there is some thought that there may be an advantage to using it to reverse metabolic acidosis and high lactate levels secondary to hypoperfusion. This could improve inotropic effect, thereby aiding recovery.[23]

The following drugs should be avoided in patients with CA toxicity:

Level of consciousness and ECG changes at presentation are the most sensitive clinical predictors of serious complications. Consider intensive care unit admission for any patient with ECG changes. Admission to a monitored bed is appropriate for patients exhibiting only anticholinergic symptoms and no cardiac manifestations.

CA toxicity typically lasts 24-48 hours following a significant overdose. However, studies have reported prolonged CA toxicity lasting as long as 4-5 days.[24]  Amitriptyline is the drug most commonly implicated in these cases.

Consultations

Poison control center and toxicologist consultation may be helpful in diagnosing and treating tricyclic antidepressant toxicity. A cardiologist should be consulted for pacemaker placement and arrhythmia management, when indicated. ICU admission is needed for patients with cardiovascular and/or neurologic manifestations.

Medication Summary

Treatment of cyclic antidepressant (CA) toxicity focuses on airway management, dysrhythmias, seizures, and hypotension. Sodium bicarbonate, benzodiazepines, and norepinephrine are the drugs of choice for these complications.

Activated charcoal (Liqui-Char)

Clinical Context:  Emergency treatment in poisoning caused by drugs and chemicals. Network of pores present in activated charcoal adsorbs 100-1000 mg of drug per gram of charcoal. May be administered with or without cathartic (eg, Sorbitol 70%), except in young pediatric patients, where electrolyte imbalance may be of concern. Does not dissolve in water.

For maximum effect, administer within 30 min of ingesting poison.

Class Summary

This agent prevents further absorption of drug and other co-ingestants from the GI tract.

Sodium bicarbonate (Neut)

Clinical Context:  First-line therapy for QRS interval >100 milliseconds or if dysrhythmias are present. Correction of acidosis promotes protein binding of CA and improves myocardial contractility. Doses or IV drip may be administered with a pH goal of 7.5-7.55. Monitor and replace potassium as needed to prevent hypokalemia.

Lidocaine (Xylocaine)

Clinical Context:  Class IB antiarrhythmic that increases electrical stimulation threshold of ventricle, suppressing automaticity of conduction through tissue. Second DOC for CA dysrhythmias.

Norepinephrine (Levophed)

Clinical Context:  Stimulates beta1- and alpha-adrenergic receptors, which, in turn, increases cardiac muscle contractility, heart rate, and vasoconstriction. As a result, systemic blood pressure and coronary blood-flow increases. DOC to treat hypotension refractory to fluid resuscitation in CA toxicity. Dopamine is second-line and less effective.

Class Summary

Sodium bicarbonate is indicated for QRS intervals greater than 100 milliseconds, seizures, acidosis (pH level < 7), hypotension, cardiac arrest, or dysrhythmia. Antidysrhythmic agents may be helpful. However, avoid certain drugs that exacerbate the cardiac effects of CAs, such as quinidine and procainamide (class IA), flecainide (class IC), and bretylium and amiodarone (class III). Vasopressors are used for the treatment of hypotension not corrected by intravenous fluids.

Lorazepam (Ativan)

Clinical Context:  Sedative hypnotic with short onset of effects and relatively long half-life (longer than diazepam).

By increasing the action of GABA, which is a major inhibitory neurotransmitter in the brain, may depress all levels of CNS, including limbic and reticular formation.

Monitoring patient's blood pressure after administering dose is important. Adjust prn.

Diazepam (Valium)

Clinical Context:  Depresses all levels of CNS (eg, limbic and reticular formation), possibly by increasing activity of GABA. Shorter acting than lorazepam.

Midazolam (Versed)

Clinical Context:  Used as alternative in termination of refractory status epilepticus. Because water soluble, takes approximately 3 times longer than diazepam to peak EEG effects. Thus, clinician must wait 2-3 min to fully evaluate sedative effects before initiating procedure or repeating dose.

Phenobarbital (Barbita, Luminal)

Clinical Context:  Used for seizures not responding to benzodiazepines. Significant respiratory depression; patient may require endotracheal intubation.

Class Summary

Benzodiazepines are preferred for treatment of seizures. Do not use barbiturates in patients with hypotension. Do not use phenytoin in patients with dysrhythmias.

Class Summary

Magnesium sulfate has been successfully used in an overdose with refractory ventricular fibrillation.[25]  In an animal study, magnesium sulfate converted ventricular tachycardia to sinus rhythm in 9 of 10 rats.[26]

Magnesium sulfate

Clinical Context:  Given parenterally, magnesium decreases acetylcholine in motor nerve terminals and acts on myocardium by slowing the rate of sinoatrial node impulse formation and prolonging conduction time. May be helpful in treating ventricular fibrillation in TCA toxicity, but further study is needed.

What is tricyclic antidepressant (TCA) toxicity?What is the pathophysiology of tricyclic antidepressant (TCA) toxicity?What is the US prevalence of tricyclic antidepressant (TCA) toxicity?What is the mortality and morbidity associated with tricyclic antidepressant (TCA) toxicity?Which patient groups have the highest prevalence of tricyclic antidepressant (TCA) toxicity?Which clinical history findings are characteristic of tricyclic antidepressant (TCA) toxicity?Which physical findings are characteristic of tricyclic antidepressant (TCA) toxicity?What are the differential diagnoses for Tricyclic Antidepressant Toxicity?What is the role of lab tests in the workup of tricyclic antidepressant (TCA) toxicity?What is the role of imaging in the workup of tricyclic antidepressant (TCA) toxicity?What is the role of ECG in the workup of tricyclic antidepressant (TCA) toxicity?What is the role of intubation in the treatment of tricyclic antidepressant (TCA) toxicity?What are the AAPCC guidelines for prehospital triage and treatment of tricyclic antidepressant (TCA) toxicity?How is asymptomatic tricyclic antidepressant (TCA) toxicity treated?How is tricyclic antidepressant (TCA) toxicity treated in the emergency department (ED)?Which medications should be avoided in patients with tricyclic antidepressant (TCA) toxicity?When is transfer to the ICU indicated for the treatment of tricyclic antidepressant (TCA) toxicity?What is the duration of tricyclic antidepressant (TCA) toxicity following a significant overdose?Which specialist consultations are beneficial to patients with tricyclic antidepressant (TCA) toxicity?What is the role of medications in the treatment of tricyclic antidepressant (TCA) toxicity?Which medications in the drug class Antidysrhythmics, V are used in the treatment of Tricyclic Antidepressant Toxicity?Which medications in the drug class Antidysrhythmics, V are used in the treatment of Tricyclic Antidepressant Toxicity?Which medications in the drug class Anticonvulsants are used in the treatment of Tricyclic Antidepressant Toxicity?Which medications in the drug class Cardiovascular agents are used in the treatment of Tricyclic Antidepressant Toxicity?Which medications in the drug class GI decontaminant are used in the treatment of Tricyclic Antidepressant Toxicity?

Author

Laura Lee S Beneke, MD, Fellow in Medical Toxicology, Department of Emergency Medicine, University of Mississippi Medical Center

Disclosure: Nothing to disclose.

Coauthor(s)

David Vearrier, MD, MPH, Professor of Emergency Medicine, Department of Emergency Medicine, University of Mississippi Medical Center

Disclosure: Nothing to disclose.

Specialty Editors

John T VanDeVoort, PharmD, Regional Director of Pharmacy, Sacred Heart and St Joseph's Hospitals

Disclosure: Nothing to disclose.

John G Benitez, MD, MPH, Associate Professor, Department of Medicine, Medical Toxicology, Vanderbilt University Medical Center; Managing Director, Tennessee Poison Center

Disclosure: Nothing to disclose.

Chief Editor

David Vearrier, MD, MPH, Professor of Emergency Medicine, Department of Emergency Medicine, University of Mississippi Medical Center

Disclosure: Nothing to disclose.

Additional Contributors

Mark A Silverberg, MD, MMB, FACEP, Assistant Professor, Associate Residency Director, Department of Emergency Medicine, State University of New York Downstate College of Medicine; Consulting Staff, Department of Emergency Medicine, Staten Island University Hospital, Kings County Hospital, University Hospital, State University of New York Downstate Medical Center

Disclosure: Nothing to disclose.

Miguel C Fernandez, MD, FAAEM, FACEP, FACMT, FACCT, Associate Clinical Professor, Department of Surgery/Emergency Medicine and Toxicology, University of Texas School of Medicine at San Antonio; Medical and Managing Director, South Texas Poison Center

Disclosure: Nothing to disclose.

Vivian Tsai, MD, MPH, FACEP, Assistant Professor of Emergency Medicine, Mount Sinai School of Medicine, Queens Hospital Center

Disclosure: Nothing to disclose.

Acknowledgements

Mark Biittner, MD Consulting Staff, Department of Emergency Medicine, Sutter Roseville Medical Center

Mark Biittner, MD is a member of the following medical societies: American College of Emergency Physicians

Disclosure: Nothing to disclose.

References

  1. Valento M, Liebelt EL. Cyclic antidepressants. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS, eds. Goldfrank's Toxicologic Emergencies. 11th ed. New York: McGraw-Hill Education; 2019. 1044-53.
  2. Shenouda R, Desan PH. Abuse of tricyclic antidepressant drugs: a case series. J Clin Psychopharmacol. 2013 Jun. 33(3):440-2. [View Abstract]
  3. Heard K, Cain BS, Dart RC, Cairns CB. Tricyclic antidepressants directly depress human myocardial mechanical function independent of effects on the conduction system. Acad Emerg Med. 2001 Dec. 8(12):1122-7. [View Abstract]
  4. Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Rivers LJ, Feldman R, et al. 2022 Annual Report of the National Poison Data System(®) (NPDS) from America's Poison Centers(®): 40th Annual Report. Clin Toxicol (Phila). 2023 Oct. 61 (10):717-939. [View Abstract]
  5. Rosenbaum TG, Kou M. Are one or two dangerous? Tricyclic antidepressant exposure in toddlers. J Emerg Med. 2005 Feb. 28(2):169-74. [View Abstract]
  6. Melanson SE, Lewandrowski EL, Griggs DA, Flood JG. Interpreting tricyclic antidepressant measurements in urine in an emergency department setting: comparison of two qualitative point-of-care urine tricyclic antidepressant drug immunoassays with quantitative serum chromatographic analysis. J Anal Toxicol. 2007 Jun. 31(5):270-5. [View Abstract]
  7. Thanacoody HK, Thomas SH. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev. 2005. 24(3):205-14. [View Abstract]
  8. Boehnert MT, Lovejoy FH Jr. Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. N Engl J Med. 1985 Aug 22. 313(8):474-9. [View Abstract]
  9. Simon M, Kaplan S, Muschler K, Hoyte C, Brent J. The role of QRS complex prolongation in predicting severe toxicity in single-xenobiotic overdose. Clin Toxicol (Phila). 2024 Jan. 62 (1):32-38. [View Abstract]
  10. Liebelt EL, Francis PD, Woolf AD. ECG lead aVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity. Ann Emerg Med. 1995 Aug. 26(2):195-201. [View Abstract]
  11. Monteban-Kooistra WE, van den Berg MP, Tulleken JE. Brugada electrocardiographic pattern elicited by cyclic antidepressants overdose. Intensive Care Med. 2006 Feb. 32(2):281-5. [View Abstract]
  12. Goldgran-Toledano D, Sideris G, Kevorkian JP. Overdose of cyclic antidepressants and the Brugada syndrome. N Engl J Med. 2002 May 16. 346(20):1591-2. [View Abstract]
  13. [Guideline] Woolf AD, Erdman AR, Nelson LS, Caravati EM, Cobaugh DJ, Booze LL, et al. Tricyclic antidepressant poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007. 45(3):203-33. [View Abstract]
  14. McCabe JL, Cobaugh DJ, Menegazzi JJ, Fata J. Experimental tricyclic antidepressant toxicity: a randomized, controlled comparison of hypertonic saline solution, sodium bicarbonate, and hyperventilation. Ann Emerg Med. 1998 Sep. 32(3 Pt 1):329-33. [View Abstract]
  15. Christophersen AB, Levin D, Hoegberg LC, Angelo HR, Kampmann JP. Activated charcoal alone or after gastric lavage: a simulated large paracetamol intoxication. Br J Clin Pharmacol. 2002 Mar. 53(3):312-7. [View Abstract]
  16. Seger DL, Hantsch C, Zavoral T, Wrenn K. Variability of recommendations for serum alkalinization in tricyclic antidepressant overdose: a survey of U.S. Poison Center medical directors. J Toxicol Clin Toxicol. 2003. 41(4):331-8. [View Abstract]
  17. Weinberg G, Ripper R, Feinstein DL, Hoffman W. Lipid emulsion infusion rescures dogs from bupivacaine-induced cardiac toxicity. Reg Anesth Pain Med. May 2003. 28(3):198-202. [View Abstract]
  18. Rothschild L, Bern S, Oswald S, Weinberg G. Intravenous lipid emulsion in cliniccal toxicology. Scandinavian Journal of Trauma, resuscitation, and Emergency Medicine. Oct 2010. 18:51:[View Abstract]
  19. Martyn Harvey, Grant Cave. Case report: successful lipid resuscitation in multi-drug overdose with predominant tricyclic antidepressant toxidrome. International Journal of Emergency Medicine. Feb 2012. 5:8. [View Abstract]
  20. Blaber MS, Khan JN, Brebner JA, McColm R. "Lipid rescue" for tricyclic antidepressant cardiotoxicity. J Emerg Med. 2012 Sep. 43 (3):465-7. [View Abstract]
  21. LipidRescue™ Resuscitation. Available at http://lipidrescue.org/. Accessed: January 22, 2023.
  22. Matsuoka M, Imai T, Iwabuchi S, Kinoshita K. Successful Treatment of Amoxapine-Induced Intractable Seizures With Intravenous Lipid Emulsion. J Emerg Med. 2022 Nov 27. [View Abstract]
  23. Mohammed T, Zahra MS, Qurashi NT, Rahman S. Case report: Management of an unknown TCA diagnosis: The importance of rapid diagnosis and the use of CVVHDF in toxin elimination. Toxicol Rep. 2023 Dec. 11:307-309. [View Abstract]
  24. O'Connor N, Greene S, Dargan P, Wyncoll D, Jones A. Prolonged clinical effects in modified-release amitriptyline poisoning. Clin Toxicol (Phila). 2006. 44(1):77-80. [View Abstract]
  25. Knudsen K, Abrahamsson J. Magnesium sulphate in the treatment of ventricular fibrillation in amitriptyline poisoning. Eur Heart J. 1997 May. 18(5):881-2. [View Abstract]
  26. Knudsen K, Abrahamsson J. Effects of magnesium sulfate and lidocaine in the treatment of ventricular arrhythmias in experimental amitriptyline poisoning in the rat. Crit Care Med. 1994 Mar. 22(3):494-8. [View Abstract]